HJB - Your Trusted Biologics CDMO Partner

HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB

HJB - Your Trusted Biologics CDMO Partner

Cn
COMPANY PROFILE

HJB was established by a seasoned team with expertise across protein, process, and manufacturing sciences. Our mission is to overcome scientific and technical barriers that impede patients' access to transformative biologic therapeutics.

At HJB, we leverage an integrated, cutting-edge technology platform to expedite the R&D process and minimize costs, facilitating rapid commercialization. We provide comprehensive, adaptable, and dependable development and manufacturing services to our clients, covering the entire lifecycle of their biologics products from research and preclinical stages, through IND filing, all clinical phases, and into commercial production.


Leadership Team

We are a group of people with passion and experience for developing innovative medicines to serve patients around the world.

Xichen ZhangPhD

General Manager, CDMO

30 years' experience in pharmaceutical/biopharmaceutical industry. Previously Angiotech, Zeneca, Supergen, Mannkind and Amgen. PhD. at QU.

Frank YePhD

Head of Technical Operations

> 25 years' experience in pharmaceutical production management, quality system and supply chain. Previously Schering-Plough, GSK, Amgen. PhD at UNC.

Chris HwangPhD

Head of Platform Technology

> 30 years' of experience in CMC development, technology transfer / scale up, manufacturing & regulatory support. Previously Genzyme and Sanofi. PhD. at MIT.

It is our mission to deliver each and every CMC package with world-leading Quality-Reliability-Speed!
Our Journey
2018

Jul.

First successful GMP batch delivered.

Oct.

First clinical supply delivered

2019

Jan.

First successful MNC IP protection audit

Jun.

First NMPA IND approval

2020

Feb.

First GMP run with Perfusion process delivered

Apr.

First FDA IND approval

2021

Feb.

First 2000L GMP run with iFB process delivered

Apr.

First FDA IND approval by Perfusion process

May.

First DP line delivered

Dec.

First process change amendment application approval

2022

Apr.

Successfully passed EU QP Audit

Jul.

Successfully completed first siRNA DP filling with high yield

Oct.

Successfully obtained NMPA and FDA approval of a process change from fed-batch to perfusion for a pivotal trial

2023

Jul.

ADC process development laboratory completed

next
prev
IP PROTECTION POLICY

Client intellectual property protection is the core value and lifeline of our CDMO business. We have established a comprehensive IP protection system based on software and hardware, including file encryption system, project file authority management, multi-level cell bank access control, etc. We carry out regular training, establish a good sense of protection and "zero tolerance" attitude among all employees and managers to maximize the protection of your IP rights.

Xueming Qian

Co-Founder & CEO

Dr. Qian has over eighteen years of industrial antibody discovery and development experience. Before starting MABSPACE, Dr. Qian was Senior VP and Head of R&D of Shenogen Pharma Group from 2010 and 2012; a Beijing-based biopharma company developing ER-a36 based anti-cancer therapies. From 1997 and 2010 Dr. Qian worked at Amgen as principal scientist and led multiple project teams to discover novel antibody therapeutics for the autoimmune diseases and metabolic disorders (bone and kidney). He is the leading inventor of multiple antibody patents. Dr. Qian graduated from Fudan University and completed his graduate studies at Columbia University and Albany Medical Center. He is a member of Antibody Society, International Society of Nephrology and BayHelix.